Company Overview and News

 
Fracking moratorium hit to under-pressure gas plays

2017-07-24 businessnews.com.au
The state government's moratorium on fracking is the latest hurdle for onshore energy hopefuls in the Perth Basin, in an environment beset by low oil prices and a lack of confidence in capital markets.
Upvote Downvote

 
Point Loma Resources Announces Closing of Joint Venture Funding Deal

2017-05-23 marketwired
CALGARY, AB--(Marketwired - May 23, 2017) - Point Loma Resources Ltd. (TSX VENTURE: PLX) (the "Corporation" or "Point Loma") is pleased to announce the closing of the previously announced disposition ("Disposition") and joint venture ("JV") with Transerv Energy Ltd. (ASX: TSV) via its Canadian subsidiary Salt Bush Energy Ltd. ("Salt Bush"). Highlights of the transaction are summarized below:
Upvote Downvote

 
Transerv Energy invests in producing oil, gas assets in Canada

2017-04-11 proactiveinvestors.com.au
Transerv Energy (ASX:TSV) is investing A$4.9 million (C$5 million) for a 20% working interest in Point Loma Resources’ (ASX:PLX) producing oil and gas assets in Alberta, Canada.
Upvote Downvote

 
Transerv buys into Canadian gas operation

2017-04-11 businessnews.com.au
Oil and gas explorer Transerv Energy is back looking for opportunities overseas, announcing today a $4.9 million farm-in agreement over a producing operation in Canada.
Upvote Downvote

 
Transerv Energy to reveal acquisition

2017-04-10 proactiveinvestors.com.au
Transerv Energy (ASX:TSV) has been granted a trading halt by the ASX, pending details of an acquisition.
Upvote Downvote

 
Point Loma Resources Announces Joint Venture Funding Deal

2017-04-10 marketwired
CALGARY, AB--(Marketwired - April 10, 2017) - Point Loma Resources Ltd. (TSX VENTURE: PLX) (the "Corporation" or "Point Loma") is pleased to announce the signing of a binding term sheet to enter into a disposition ("Disposition") and joint venture ("JV") with Transerv Energy Ltd. (ASX: TSV) via its Canadian subsidiary Salt Bush Energy Ltd. ("Salt Bush"). Highlights of the transaction are summarized below:
Upvote Downvote

 
$52m Warro impairment for Alcoa

2017-01-04 businessnews.com.au
A $52 million impairment has been taken on Alcoa World Alumina Corporation’s share of the Warro gas project in the Perth Basin, after the company determined exploration results did not support the existing carrying value.
Upvote Downvote

 
Transerv blindsided by Origin's spin-out plans

2016-12-07 businessnews.com.au
Shares in oil and gas explorer Transerv Energy tumbled today as managing director Stephen Keenihan announced his resignation in the wake of news yesterday that the company’s proposal to acquire assets owned by Origin Energy had been terminated.
Upvote Downvote

 
Transerv blind-sighted by Origin's demerger plans

2016-12-07 businessnews.com.au
Shares in oil and gas explorer Transerv Energy tumbled today as managing director Stephen Keenihan announced his resignation in the wake of news yesterday that the company’s proposal to acquire assets owned by Origin Energy had been terminated.
Upvote Downvote

 
Transerv Energy to respond to ASX price and volume query

2016-10-23 proactiveinvestors.com.au
Shares in the company were halted late in Friday's session, after hitting $0.015 intra-day, up from the $0.012 open, with 6.4 million shares changing hands.
Upvote Downvote

 
Transerv Energy moves closer to completion of Xanadu-1 farm out

2016-09-23 oilvoice
On 7 July 2016, Transerv Energy Ltd (TSV) announced the formation of a strategic alliance with Norwest Energy Ltd (NWE) to facilitate the farmout and drilling of the 160 million barrel Xanadu Prospect in TP/15. On 19 September, NWE announced that it has executed a term sheet with Triangle Energy (Global) Limited (Triangle) for Triangle to earn a 30% interest in TP/15 by paying 40% of the costs of the Xanadu-1 well.
Upvote Downvote

 
PPL’s Gambat South well yields possible tight gas discovery

2016-07-19 ogj
The Pakistan Petroleum Ltd.-operated Hadi X-1A exploration well, located on the Gambat South block in the Sanghar district of Pakistan’s Sindh province, flowed 0.85 MMscfd on a 32/64-in. choke, confirming the presence of natural gas.
Upvote Downvote

 
Devon STACK spacing test flows 1,400 boe/d/well

2016-07-19 ogj
Devon Energy Corp.’s Alma spacing pilot in the overpressured oil window of the Oklahoma STACK play tested five wells per section across a single interval in the Mississippian Upper Meramec, delivering 30-day production rates averaging 1,400 boe/d/well, of which 60% was light oil.
Upvote Downvote

 
EIA: US crude inventories fall 2.5 million bbl

2016-07-13 ogj
US commercial crude oil inventories, excluding those in the Strategic Petroleum Reserve, fell 2.5 million bbl during the week ended July 8 compared with the previous week’s total, according to the US Energy Information Administration’s latest Petroleum Status Report.
Upvote Downvote

 
EIA: Latest STEO forecasts oil market balancing in 2017

2016-07-12 ogj
Global inventory builds of petroleum and other liquid fuels will average 900,000 b/d in 2016, slowing down from 1.9 million b/d in 2015, according to the July Short-Term Energy Outlook from the US Energy Information Administration. EIA also expects the market to reach balance in 2017, with inventory draws during the second half of the year averaging 300,000 b/d.
Upvote Downvote

Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

2018-04-25 - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN: Amazon.com, Inc Analysis and Research Report

2018-04-25 - Asif

Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...